Mumbai/Delhi: Lupin Limited, a global pharmaceutical leader, today announced a strategic collaboration with Honeywell to incorporate HFO Technology – its cutting-edge Solstice Air (HFO-1234ze(E) cGMP) propellant – into Lupin’s next-generation respiratory inhalers.
HFO Technology
With this move, Lupin is poised to become the first Indian pharmaceutical company to adopt Hydrofluoroolefin (HFO) technology at scale for pressurized metered-dose inhalers (pMDIs), marking a transformative milestone in sustainable healthcare.
Solstice Air by Honeywell is a medical-grade, non-flammable propellant with near-zero global warming potential (GWP), offering an eco-conscious alternative to traditional hydrofluorocarbon (HFC)-based inhaler propellants.
Its application in asthma and chronic obstructive pulmonary disease (COPD) treatments can reduce greenhouse gas emissions by up to 99.9%, providing a major environmental benefit alongside effective patient care.
A Strategic Shift Toward Green Inhalers
Lupin’s commitment to deploying HFO technology reinforces its focus on innovation and environmental stewardship in respiratory therapy. By integrating Honeywell’s advanced propellant into its product pipeline, Lupin will play a pivotal role in redefining industry standards for climate-friendly drug delivery mechanisms.
Vinita Gupta, CEO, Lupin, commented: “Our partnership with Honeywell is a powerful step toward delivering high-quality, patient-centric medicines while advancing sustainability. The adoption of Solstice Air will enable us to significantly reduce the environmental footprint of our respiratory products without compromising on efficacy.”
Ashish Modi, President of Honeywell India, added: “Solstice Air demonstrates how breakthrough technology can simultaneously improve healthcare outcomes and support climate goals. Through this collaboration, we’re enabling Lupin to take the lead in transforming India’s respiratory care segment with next-gen HFO technology.”
While the agreement is subject to final negotiations and execution of definitive documents, the announcement reflects strong intent from both companies to lead the global transition toward sustainable pharma innovation.
This initiative is part of a larger industry trend to align healthcare with climate action. As regulations around high-GWP medical products tighten globally, Lupin’s early adoption of HFO-based pMDIs sets a precedent for eco-friendly practices in pharmaceutical manufacturing and respiratory care delivery.
